[포스트 IPO]③ 기술특례 성공사례 큐로셀, …1.5년 남은 규제벽

Curesell's launch of Korea's first domestically developed CAR-T therapy demonstrates the effectiveness of technology-driven IPO programs in accelerating biotech innovation. Yet the company's zero-revenue status and impending 2027 regulatory crisis highlight the critical gap between supporting innovation and enforcing financial discipline in biotech-heavy markets.